Market Cap 1.34B
Revenue (ttm) 272.30M
Net Income (ttm) -5.14M
EPS (ttm) N/A
PE Ratio 82.87
Forward PE 74.88
Profit Margin -1.89%
Debt to Equity Ratio 4.67
Volume 402,100
Avg Vol 755,762
Day's Range N/A - N/A
Shares Out 37.23M
Stochastic %K 82%
Beta 0.31
Analysts Strong Sell
Price Target $66.71

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 733 4730
Address:
1A Burton Hills Boulevard, Suite 200, Nashville, United States
flash9875
flash9875 Apr. 13 at 5:43 PM
$HROW BTIG fireside chat on tuesday. this is a private session with Baum and the analysts.....also BTIG clients (institutions etc) participate/login. Hope we can get some updates over the upcoming few days...perhaps the biggest one to look for is an update by BTIG on HROW
1 · Reply
flash9875
flash9875 Apr. 13 at 2:10 PM
$HROW We deserve to be $50 plus now. With good guidance and continued vevye numbers from Bloomberg we should march to 60 plus…and if on target with sales ramp we should be $80 plus by December ….if not more… it’s coming…
0 · Reply
HROW200
HROW200 Apr. 12 at 7:25 PM
$HROW Looks like management is indeed trying to convert cataract surgeons to Triesence before launching BYQLOVI. I hear it’s coming this summer.
1 · Reply
Finnish_boy
Finnish_boy Apr. 11 at 7:44 AM
$HROW $35->$45->$35->$100.. i follow this.
1 · Reply
Finnish_boy
Finnish_boy Apr. 11 at 7:24 AM
$HROW Shorts will play Q1 report, no doubt. Short squeeze is not possible with this stock, they will short more if necessary. Q1 revenue will be 52-55M? Down -40% from Q4. That's ugly if you have no idea about the stock. We need very solid outlook commentary, byqlovi launch, j-code decision, strong vevye data, maybe acquisition, hype about Byooviz and we hit ATH late Q2. But most likely ATH in Q3 or by Q4 anyways. But yes, i will buy any potential dip VERY HARD. This is the final opportunity to hop on the train. We are very lucky that SP still this low. It shouldnt be. Dont miss this!
1 · Reply
Tennis_4567
Tennis_4567 Apr. 10 at 10:41 PM
$HROW short interest jumped to 6.9 million shares.
1 · Reply
flash9875
flash9875 Apr. 10 at 7:39 PM
$HROW shake those boobies !
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Apr. 9 at 11:40 PM
0 · Reply
Finnish_boy
Finnish_boy Apr. 9 at 5:29 PM
$HROW Also, reportin very weak Q1 revenue number and at the same time adjusting FY26 guidance higher would be quite a move😂but yea, they dont do that and mgt doesnt care about price action yet when huge journey ahead. SP will catch up the fundamentals later
1 · Reply
Finnish_boy
Finnish_boy Apr. 9 at 5:23 PM
$HROW Q1 earnings report can be massive bear trap. Q1 revenue number will be weak but think mgt is building a tsunami of press releases.
0 · Reply
Latest News on HROW
Harrow to Present at Two Investor Conferences in December

Nov 24, 2025, 7:00 AM EST - 5 months ago

Harrow to Present at Two Investor Conferences in December


Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Nov 18, 2025, 7:00 AM EST - 5 months ago

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals


Harrow Announces Third Quarter 2025 Financial Results

Nov 10, 2025, 4:05 PM EST - 5 months ago

Harrow Announces Third Quarter 2025 Financial Results


ImprimisRx Announces Leadership Changes

Oct 6, 2025, 7:00 AM EDT - 6 months ago

ImprimisRx Announces Leadership Changes


Harrow to Acquire Melt Pharmaceuticals

Sep 26, 2025, 7:00 AM EDT - 7 months ago

Harrow to Acquire Melt Pharmaceuticals


Harrow Launches Harrow Access for All (HAFA)

Sep 25, 2025, 4:05 PM EDT - 7 months ago

Harrow Launches Harrow Access for All (HAFA)


Harrow Announces Agenda and Speakers for Investor & Analyst Day

Sep 15, 2025, 7:00 AM EDT - 7 months ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day


Harrow Announces Second-Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 8 months ago

Harrow Announces Second-Quarter 2025 Financial Results


Harrow to Present at Two Investor Conferences in May

May 14, 2025, 7:00 AM EDT - 11 months ago

Harrow to Present at Two Investor Conferences in May


Harrow Announces First-Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 1 year ago

Harrow Announces First-Quarter 2025 Financial Results


NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 24, 2025, 10:00 AM EDT - 1 year ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.


Harrow Launches VEVYE® Access for All

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Harrow Launches VEVYE® Access for All


Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Jan 7, 2025, 7:00 AM EST - 1 year ago

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer


Harrow Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:34 PM EST - 1 year ago

Harrow Announces Third Quarter 2024 Financial Results


Harrow Announces Market Access Wins for VEVYE®

Nov 12, 2024, 7:00 AM EST - 1 year ago

Harrow Announces Market Access Wins for VEVYE®


flash9875
flash9875 Apr. 13 at 5:43 PM
$HROW BTIG fireside chat on tuesday. this is a private session with Baum and the analysts.....also BTIG clients (institutions etc) participate/login. Hope we can get some updates over the upcoming few days...perhaps the biggest one to look for is an update by BTIG on HROW
1 · Reply
flash9875
flash9875 Apr. 13 at 2:10 PM
$HROW We deserve to be $50 plus now. With good guidance and continued vevye numbers from Bloomberg we should march to 60 plus…and if on target with sales ramp we should be $80 plus by December ….if not more… it’s coming…
0 · Reply
HROW200
HROW200 Apr. 12 at 7:25 PM
$HROW Looks like management is indeed trying to convert cataract surgeons to Triesence before launching BYQLOVI. I hear it’s coming this summer.
1 · Reply
Finnish_boy
Finnish_boy Apr. 11 at 7:44 AM
$HROW $35->$45->$35->$100.. i follow this.
1 · Reply
Finnish_boy
Finnish_boy Apr. 11 at 7:24 AM
$HROW Shorts will play Q1 report, no doubt. Short squeeze is not possible with this stock, they will short more if necessary. Q1 revenue will be 52-55M? Down -40% from Q4. That's ugly if you have no idea about the stock. We need very solid outlook commentary, byqlovi launch, j-code decision, strong vevye data, maybe acquisition, hype about Byooviz and we hit ATH late Q2. But most likely ATH in Q3 or by Q4 anyways. But yes, i will buy any potential dip VERY HARD. This is the final opportunity to hop on the train. We are very lucky that SP still this low. It shouldnt be. Dont miss this!
1 · Reply
Tennis_4567
Tennis_4567 Apr. 10 at 10:41 PM
$HROW short interest jumped to 6.9 million shares.
1 · Reply
flash9875
flash9875 Apr. 10 at 7:39 PM
$HROW shake those boobies !
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Apr. 9 at 11:40 PM
0 · Reply
Finnish_boy
Finnish_boy Apr. 9 at 5:29 PM
$HROW Also, reportin very weak Q1 revenue number and at the same time adjusting FY26 guidance higher would be quite a move😂but yea, they dont do that and mgt doesnt care about price action yet when huge journey ahead. SP will catch up the fundamentals later
1 · Reply
Finnish_boy
Finnish_boy Apr. 9 at 5:23 PM
$HROW Q1 earnings report can be massive bear trap. Q1 revenue number will be weak but think mgt is building a tsunami of press releases.
0 · Reply
flash9875
flash9875 Apr. 9 at 4:08 PM
$HROW the next potential kicker…The Saturday morning (8:00 AM ET) session is the one to watch. • The "Real-World" Release: This is when the Epitropoulos data hits the wire. It provides the "Scientific Permission" for doctors to switch from Xiidra to Vevye. • The App Update: Historically, the ASCRS Meeting App releases the full text of accepted abstracts and electronic posters to registered attendees the morning the conference opens—which is Friday, April 10. If you have a contact "on the floor," they may see the summaries tomorrow. 3. SYSTEM ALERTS / NUDGES: THE "SIGHTLINE" ECHO • Alert: The "Data" Lag. While the data drops Saturday morning, the market "Algos" often don't process the clinical significance until the Monday morning (April 13) open.
0 · Reply
flash9875
flash9875 Apr. 9 at 1:01 PM
$HROW Strategic Significance: The "Peer-to-Peer" Audition This is the "Institutional Premiere" I mentioned. By sitting on this specific panel, Baum is no longer being treated as the CEO of a "compounding shop"—he is being positioned by ASCRS as a peer to the leaders of Alcon and AbbVie. What to watch for (Today’s Breadcrumbs): 1. Capital Allocation: Watch how Baum discusses the $122M War Chest compared to the "Capital Discipline" of the larger giants. 2. M&A Talk: The agenda explicitly mentions "growth and M&A realities." This is where the "Whales" will be listening for any hints of Harrow as a consolidator—or a target. 3. The "One Harrow" Narrative: Baum will likely emphasize how the 100-rep expansion (May launch) is designed to scale across the specialty products (\bm{J3300}, Vevye, Ilevro) in a way the big guys' rigid portfolios can't.
0 · Reply
flash9875
flash9875 Apr. 9 at 12:59 PM
$HROW The SightLine at ASCRS program in Washington, D.C., officially kicked off at 8:30 AM ET (5:30 AM PST). Based on the detailed agenda, Baum’s panel is one of the very first sessions of the day, following the opening remarks from ASCRS leadership and JP Morgan. The "Executive Viewpoint" Roundtable • Time: Approximately 9:00 AM – 10:00 AM ET (Started roughly at 6:00 AM PST). • Moderator: Jim Mazzo (Neurotech). • The Panel: Mark Baum (Harrow) is sitting alongside the "Titans": • Julie Brewer (Alcon) • Kelly Giuffrida (AbbVie) • Brent Saunders (Bausch + Lomb)
0 · Reply
Fullback
Fullback Apr. 9 at 11:36 AM
$HROW Short report for 3-31-26 Settlement date should be published tomorrow. SP is low, don't see how it increases any. Will be curious to see the numbers.
0 · Reply
flash9875
flash9875 Apr. 8 at 2:56 PM
$HROW like a cheap,lap,dance…
0 · Reply
Finnish_boy
Finnish_boy Apr. 8 at 1:24 PM
$HROW B Riley made some quick math. Stock should be anyways at least double of current price. But sentiment mood swings have caused toxic environment. Also, too less people know about this stock yet.
0 · Reply
Finnish_boy
Finnish_boy Apr. 8 at 12:19 PM
$HROW XIIDRA -1, VEVYE +1
1 · Reply
Finnish_boy
Finnish_boy Apr. 8 at 12:18 PM
$HROW J-CODE decision this month, Byqlovi launch next month, and acquisition (not Atropine) by June. ATH in late Q2 or Q3.
1 · Reply
HROW200
HROW200 Apr. 7 at 11:23 PM
$HROW With ASCRS Thursday through Monday, odds are good Harrow will have a PR. Isn’t it past due for the release of BYQLOVI!
2 · Reply
Finnish_boy
Finnish_boy Apr. 7 at 10:30 PM
$HROW S&P500 up from bottom 5%. To ATH 5%. Nobody knows but i think bottoms in. HROW bottom in also. We dont see 20s.
0 · Reply
Finnish_boy
Finnish_boy Apr. 7 at 10:26 PM
$HROW Everything will soar bc stock markets are cheap overall. AI boom is massive. We are in the early innings. Geopolitical issues work usually amazing buying opportunities when there is risk-off mood a while. ATHs in Q2, HROW ATH late June-Q3. Geopolitical issues can continue and stock markets still go up. But usually they will be resolved in weeks.
0 · Reply
flash9875
flash9875 Apr. 7 at 5:38 PM
$HROW taco taco
0 · Reply